Sun, Novartis reach settlement over ExelonBS Reporter / Mumbai December 6, 2007Sun Pharmaceutical Industries today announced it has reached a settlement with Novartis stipulating a dismissal of the lawsuits filed in the United States against it regarding submission of an abbreviated new drug application (ANDA) for a generic version of Exelon, i.e. rivastigmine tartrate capsules.Under the terms of the settlement agreement, Sun Pharma will not market generic Exelon in the US until sometime prior to the expiration of the patents covering Exelon. The specific date on which Sun may launch and the other terms of the agreement are confidential.Earlier, USFDA had granted final approval for Sun
